MedTrace Logo

PROUD Study: A Prospective Study on the Usage Patterns of Doripenem in the Asia Pacific Region

NCT00986102 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 216

Last updated 2024-11-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to understand the utilization patterns of doripenem in Asia Pacific, including the profile of the patients treated with carbapenems.

Conditions

Interventions

DRUG

doripenem

500mg vial by injection every 8 hours for 5 to 14 days

Sponsors & Collaborators

  • Johnson & Johnson (Hong Kong) Ltd.

    collaborator UNKNOWN

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-17
Primary Completion
2011-09-05
Completion
2011-09-09

Countries

  • Hong Kong
  • Indonesia
  • Malaysia
  • Singapore
  • Vietnam

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00986102 on ClinicalTrials.gov